X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ITI will employ CoImmune’s process for manufacturing and cGMP work for the advancement of ITI-1020, ITI’s autologous dendritic cell (DC) investigational vaccine loading with mRNA encoding LAMP: pp65 for the treatment of newly diagnosed glioblastoma (GBM).
Lead Product(s): ITI-1020
Therapeutic Area: Oncology Product Name: ITI-1020
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Immunomic Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 19, 2020
Details:
CoImmune will use the proceeds from the financing to fund its ongoing Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma and multiple Phase 1-2a trials with its newly acquired technology, CAR-CIK, in five leukemia and lymphoma settings.
Lead Product(s): CMN-001
Therapeutic Area: Oncology Product Name: CMN-001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: FIDIM Group
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
